vs
AXCELIS TECHNOLOGIES INC（ACLS）与ADMA BIOLOGICS, INC.（ADMA）财务数据对比。点击上方公司名可切换其他公司
AXCELIS TECHNOLOGIES INC的季度营收约是ADMA BIOLOGICS, INC.的1.7倍（$238.3M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 14.4%，领先21.1%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -5.6%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $-8.9M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -2.8%）
Axcelis Technologies是一家美国半导体设备供应商，1995年成立，总部位于美国马萨诸塞州贝弗利。公司面向全球半导体制造行业，从事半导体生产核心设备的设计、制造及服务，主营产品包括高中电流、高能离子注入系统以及半导体芯片制造用固化系统。
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
ACLS vs ADMA — 直观对比
营收规模更大
ACLS
是对方的1.7倍
$139.2M
营收增速更快
ADMA
高出24.0%
-5.6%
净利率更高
ADMA
高出21.1%
14.4%
自由现金流更多
ADMA
多$43.5M
$-8.9M
两年增速更快
ADMA
近两年复合增速
-2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $238.3M | $139.2M |
| 净利润 | $34.3M | $49.4M |
| 毛利率 | 47.0% | 63.8% |
| 营业利润率 | 15.2% | 45.1% |
| 净利率 | 14.4% | 35.5% |
| 营收同比 | -5.6% | 18.4% |
| 净利润同比 | -31.3% | -55.9% |
| 每股收益（稀释后） | $1.11 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLSADMA
| Q4 25 | $238.3M | $139.2M | ||
| Q3 25 | $213.6M | $134.2M | ||
| Q2 25 | $194.5M | $122.0M | ||
| Q1 25 | $192.6M | $114.8M | ||
| Q4 24 | $252.4M | $117.5M | ||
| Q3 24 | $256.6M | $119.8M | ||
| Q2 24 | $256.5M | $107.2M | ||
| Q1 24 | $252.4M | $81.9M |
净利润ACLSADMA
| Q4 25 | $34.3M | $49.4M | ||
| Q3 25 | $26.0M | $36.4M | ||
| Q2 25 | $31.4M | $34.2M | ||
| Q1 25 | $28.6M | $26.9M | ||
| Q4 24 | $50.0M | $111.9M | ||
| Q3 24 | $48.6M | $35.9M | ||
| Q2 24 | $50.9M | $32.1M | ||
| Q1 24 | $51.6M | $17.8M |
毛利率ACLSADMA
| Q4 25 | 47.0% | 63.8% | ||
| Q3 25 | 41.6% | 56.3% | ||
| Q2 25 | 44.9% | 55.1% | ||
| Q1 25 | 46.1% | 53.2% | ||
| Q4 24 | 46.0% | 53.9% | ||
| Q3 24 | 42.9% | 49.8% | ||
| Q2 24 | 43.8% | 53.6% | ||
| Q1 24 | 46.0% | 47.8% |
营业利润率ACLSADMA
| Q4 25 | 15.2% | 45.1% | ||
| Q3 25 | 11.7% | 38.0% | ||
| Q2 25 | 14.9% | 35.1% | ||
| Q1 25 | 15.1% | 30.4% | ||
| Q4 24 | 21.6% | 32.6% | ||
| Q3 24 | 18.3% | 33.1% | ||
| Q2 24 | 20.6% | 36.6% | ||
| Q1 24 | 22.4% | 26.7% |
净利率ACLSADMA
| Q4 25 | 14.4% | 35.5% | ||
| Q3 25 | 12.2% | 27.1% | ||
| Q2 25 | 16.1% | 28.1% | ||
| Q1 25 | 14.8% | 23.4% | ||
| Q4 24 | 19.8% | 95.2% | ||
| Q3 24 | 18.9% | 30.0% | ||
| Q2 24 | 19.8% | 29.9% | ||
| Q1 24 | 20.4% | 21.7% |
每股收益（稀释后）ACLSADMA
| Q4 25 | $1.11 | $0.20 | ||
| Q3 25 | $0.83 | $0.15 | ||
| Q2 25 | $0.98 | $0.14 | ||
| Q1 25 | $0.88 | $0.11 | ||
| Q4 24 | $1.54 | $0.45 | ||
| Q3 24 | $1.49 | $0.15 | ||
| Q2 24 | $1.55 | $0.13 | ||
| Q1 24 | $1.57 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $374.3M | $87.6M |
| 总债务越低越好 | — | $72.1M |
| 股东权益账面价值 | $1.0B | $477.3M |
| 总资产 | $1.4B | $624.2M |
| 负债/权益比越低杠杆越低 | — | 0.15× |
8季度趋势，按日历期对齐
现金及短期投资ACLSADMA
| Q4 25 | $374.3M | $87.6M | ||
| Q3 25 | $449.6M | $61.4M | ||
| Q2 25 | $549.8M | $90.3M | ||
| Q1 25 | $587.1M | $71.6M | ||
| Q4 24 | $571.3M | $103.1M | ||
| Q3 24 | $579.4M | $86.7M | ||
| Q2 24 | $548.3M | $88.2M | ||
| Q1 24 | $530.2M | $45.3M |
总债务ACLSADMA
| Q4 25 | — | $72.1M | ||
| Q3 25 | — | $72.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $72.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACLSADMA
| Q4 25 | $1.0B | $477.3M | ||
| Q3 25 | $1.0B | $431.2M | ||
| Q2 25 | $1.0B | $398.3M | ||
| Q1 25 | $1.0B | $373.4M | ||
| Q4 24 | $1.0B | $349.0M | ||
| Q3 24 | $975.6M | $231.9M | ||
| Q2 24 | $934.9M | $188.3M | ||
| Q1 24 | $901.7M | $153.7M |
总资产ACLSADMA
| Q4 25 | $1.4B | $624.2M | ||
| Q3 25 | $1.4B | $568.7M | ||
| Q2 25 | $1.3B | $558.4M | ||
| Q1 25 | $1.3B | $510.6M | ||
| Q4 24 | $1.3B | $488.7M | ||
| Q3 24 | $1.3B | $390.6M | ||
| Q2 24 | $1.3B | $376.4M | ||
| Q1 24 | $1.3B | $350.9M |
负债/权益比ACLSADMA
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.6M | $35.6M |
| 自由现金流经营现金流 - 资本支出 | $-8.9M | $34.6M |
| 自由现金流率自由现金流/营收 | -3.7% | 24.8% |
| 资本支出强度资本支出/营收 | 1.0% | 0.8% |
| 现金转化率经营现金流/净利润 | -0.19× | 0.72× |
| 过去12个月自由现金流最近4个季度 | $107.0M | $27.8M |
8季度趋势，按日历期对齐
经营现金流ACLSADMA
| Q4 25 | $-6.6M | $35.6M | ||
| Q3 25 | $45.4M | $13.3M | ||
| Q2 25 | $39.7M | $21.1M | ||
| Q1 25 | $39.8M | $-19.7M | ||
| Q4 24 | $12.8M | $50.2M | ||
| Q3 24 | $45.7M | $25.0M | ||
| Q2 24 | $40.1M | $45.6M | ||
| Q1 24 | $42.2M | $-2.2M |
自由现金流ACLSADMA
| Q4 25 | $-8.9M | $34.6M | ||
| Q3 25 | $43.3M | $-1.1M | ||
| Q2 25 | $37.7M | $18.7M | ||
| Q1 25 | $34.8M | $-24.4M | ||
| Q4 24 | $8.1M | $47.5M | ||
| Q3 24 | $41.8M | $24.0M | ||
| Q2 24 | $38.1M | $43.6M | ||
| Q1 24 | $40.6M | $-4.6M |
自由现金流率ACLSADMA
| Q4 25 | -3.7% | 24.8% | ||
| Q3 25 | 20.3% | -0.8% | ||
| Q2 25 | 19.4% | 15.3% | ||
| Q1 25 | 18.1% | -21.2% | ||
| Q4 24 | 3.2% | 40.4% | ||
| Q3 24 | 16.3% | 20.0% | ||
| Q2 24 | 14.8% | 40.7% | ||
| Q1 24 | 16.1% | -5.6% |
资本支出强度ACLSADMA
| Q4 25 | 1.0% | 0.8% | ||
| Q3 25 | 0.9% | 10.7% | ||
| Q2 25 | 1.0% | 2.0% | ||
| Q1 25 | 2.6% | 4.1% | ||
| Q4 24 | 1.8% | 2.3% | ||
| Q3 24 | 1.5% | 0.9% | ||
| Q2 24 | 0.8% | 1.9% | ||
| Q1 24 | 0.6% | 2.9% |
现金转化率ACLSADMA
| Q4 25 | -0.19× | 0.72× | ||
| Q3 25 | 1.75× | 0.36× | ||
| Q2 25 | 1.27× | 0.62× | ||
| Q1 25 | 1.39× | -0.73× | ||
| Q4 24 | 0.26× | 0.45× | ||
| Q3 24 | 0.94× | 0.70× | ||
| Q2 24 | 0.79× | 1.42× | ||
| Q1 24 | 0.82× | -0.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLS
| Products | $224.6M | 94% |
| Services | $13.7M | 6% |
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
